Similar Items: Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
- Elevated sclerostin levels in cerebrospinal fluid are associated with cognitive impairment in the Alzheimer's disease continuum
- Simulation of long‐term lecanemab treatment effect on Alzheimer's disease progression
- Longitudinal changes in DTI‐ALPS and choroid plexus volume relative to CSF biomarkers during lecanemab treatment in mild cognitive impairment: A pilot study
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- Real‐world use of lecanemab: patient pathway findings from a US multicenter study
- Cerebrospinal fluid NPTX2/p‐tau ratio as a biomarker for cognitive decline in neurodegenerative diseases